AustralianSuper Pty Ltd Has $203.27 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

AustralianSuper Pty Ltd boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,222,695 shares of the company’s stock after purchasing an additional 1,329,319 shares during the period. Teva Pharmaceutical Industries accounts for about 1.0% of AustralianSuper Pty Ltd’s portfolio, making the stock its 23rd biggest holding. AustralianSuper Pty Ltd owned about 0.81% of Teva Pharmaceutical Industries worth $203,268,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. FMR LLC increased its position in Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Janus Henderson Group PLC increased its holdings in Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after purchasing an additional 4,732,374 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Teva Pharmaceutical Industries by 237.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after buying an additional 2,204,623 shares during the period. Finally, State Street Corp grew its position in shares of Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after buying an additional 1,778,268 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $16.59 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The stock has a 50-day moving average of $20.01 and a 200-day moving average of $18.50. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.